Table 1.
Characteristics of the included studies.
| Trials | Sample size (E/C) | Gender | Age (yr) | clinical stage | Experimental group (E) | Control group (C) | Period | Outcome measure |
|---|---|---|---|---|---|---|---|---|
| Zhu W [17] | 32/32 | M: 16, F: 16/M: 15, F: 17 |
32-74 (61.7)/34-72 (62.8) | III: 15, IV: 17/III: 16, IV: 16 | Cinobufacini injection 30 ml iv. Qd + C | Xelox regimen | 4 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO) |
|
| ||||||||
| Zou H [18] | 30/30 | M: 13, F: 17/M: 21, F: 9 |
59.1/56.5 | III, IV | Cinobufacini injection 20 ml iv. Qd + C | EOF regimen | 6 weeks | tumor response (RECIST), Kamofsky Score, Side-effects of chemotherapy (WHO) |
|
| ||||||||
| Zhang C [19] | 35/32 | M: 28, F: 7/M: 23, F: 9 |
46-82 (64)/42-79 (66) | III: 15, IV: 20/III: 13, IV: 19 | Cinobufacini injection 20ml iv. Qd + C | ELF regimen | 8 weeks | tumor response (UICC), Side-effects of chemotherapy (WHO) |
|
| ||||||||
| Guo C [20] | 43/43 | M: 62, F: 24 |
43-74 (55) | IV | Cinobufacini injection 20 ml iv. Qd + C | Docetaxel | 9 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO), analgesic effect |
|
| ||||||||
| Zhang Y [21] | 28/29 | None | 42-71 (57)/35-69 (54) | IV | Cinobufacini injection 50 ml iv. Qd + C | oxaliplatin + floxuridine | 9 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO), analgesic effect, 1 year and 2 year survival time |
|
| ||||||||
| Chen G [22] | 62/86 | M: 56, F: 30/M: 39, F: 23 |
65-87 (71.8 ± 18.6)/64-89 (73.1 ± 22.3) | IV | Cinobufacini injection 10 ml iv. Tid + C | Capecitabine | 6 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO), overall survival time |
|
| ||||||||
| Xu D [23] | 30/30 | M: 20, F: 10/M: 21, F: 9 |
66.3 ± 4.6/65.0 ± 3.9 | IV | Cinobufacini injection 20 ml iv. Qd + C | Capecitabine | 6 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO), analgesic effect |
|
| ||||||||
| Zhang Z [24] | 30/30 | None | 35-79 (53)/33-75 (56) | IV | Cinobufacini injection 20ml iv. Qd + C | Hydroxycamptothecin | 6 weeks | tumor response (WHO), Kamofsky Score, Side-effects of chemotherapy (WHO), analgesic effect |
|
| ||||||||
| Lu C [25] | 31/31 | M: 34 F: 28 |
37-71 (54 ± 17) | III | Cinobufacini injection 20 ml iv. Qd + C | FOLFOX4 regimen | 9 weeks | tumor response (WHO), immune regulation |
|
| ||||||||
| Wang Y [26] | 36/32 | M: 48 F: 20 |
40-72 (54) | IV | Cinobufacini injection 20 ml iv. Qd + C | FOLFOX4 regimen | 8 weeks | tumor response (WHO), Side-effects of chemotherapy (WHO), |
|
| ||||||||
| Ren L [27] | 32/22 | Unclear | 40-68 (53) | IV | Cinobufacini injection 20 ml iv. Qd + C | FOLFOX regimen | 6 weeks | tumor response (WHO), Side-effects of chemotherapy (WHO), Kamofsky Score, |
|
| ||||||||
| Chen H [28] | 34/33 | M: 20, F: 14/M:20, F: 13 |
50.6/40.9 | III: 23, IV: 11/III: 24, IV: 9 | Cinobufacini injection 30 ml iv. Qd + C | TPF regimen | 6 weeks | tumor response (WHO), Side-effects of chemotherapy (WHO) |
ELF regimen: oxaliplatin + epirubicin + floxuridine; ELF regimen: etoposide + cisplatin+ floxuridine; Xelox regimen: oxaliplatin + capecitabine; FOLFOX4 regimen: oxaliplatin + floxuridine + leucovorin; and TPF regimen: paclitaxel + cisplatin +floxuridine.